Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (29325)	2/1/2005 1:36:48 PM
From: cavan	Read Replies (2) \| Respond to of 120415

This is one from the past!Northwest Biotherapeutics, Inc. to Initiate Phase III Clinical Trial for Prostate Cancer Monday January 31, 10:47 pm ET Dendritic Cell-Based DCVax(R)-Prostate Phase III IND Cleared by FDA for Assessment in Non-Metastatic Hormone Independent Prostate Cancer Patients BOTHELL, Wash., Jan. 31 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBT.OB - News) today announced that it has received clearance from the Food and Drug Administration (FDA) to begin assessment of its cell based dendritic cell product candidate, DCVax(R)-Prostate, in a Phase III clinical trial. This trial is based on promising clinical data from a previously conducted Phase I/II clinical trial. The double blinded, placebo controlled Phase III clinical trial is expected to enroll about 600 patients at 30-50 sites throughout the United States. ADVERTISEMENT "The initiation of this Phase III trial for non-metastatic hormone independent prostate cancer patients represents a major milestone achievement for our lead product candidate, DCVax(R)-Prostate, and for implementation of our new business strategy, and progress with our recent recapitalization agreement with Toucan Capital of Bethesda, MD" stated Alton L. Boynton, Ph.D., President, Chief Operating Officer, and a co-founder of NWBT. "I believe DCVax(R)-Prostate represents a promising new treatment for non-metastatic hormone independent prostate cancer for which there is currently no FDA approved product." Northwest Biotherapeutics previously received clearance through the FDA for a Phase II clinical trial for DCVax(R)-Brain, a promising new treatment for Glioblastoma Multiforme which is the most common, and lethal form of brain cancer. The company intends to begin this multi-site clinical trial later this year. In addition, the DCVax(R) platform can be used for multiple cancer indications, and NWBT has completed preclinical work targeted for a Phase I clinical trial for non-small cell lung cancer and head and neck cancer. About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The company has completed Phase I/II clinical trials for its lead product candidate DCVax(R) -- Prostate and completed preclinical work for several other product candidates targeting multiple cancers. Three technologies form the basis of our product candidates: a dendritic cell-based immunotherapy platform applicable to multiple cancers; a therapeutic monoclonal antibody product candidate applicable to multiple cancer types; and an antibody-based imaging agent for metastatic prostate cancer. Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the planned Phase III trial of DCVAX(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVAX(R)-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVAX(R)-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws. -------------------------------------------------------------------------------- Source: Northwest Biotherapeutics, Inc.

To: GARY P GROBBEL who wrote (29325)	2/1/2005 2:26:52 PM
From: rrufff	Read Replies (1) \| Respond to of 120415

BTN - 5.42 + .32 continues to recover With about 13.5 million shares o/s, they should be running about .50 a share in Net Income and over $3.25 a share in revenues. With steady growth record, it should be selling PE of 20 or P/S of 3, both of which still gives a shot at almost a double from here. Balance sheet is pristine and they are a takeover candidate.